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Summary
 
A characteristic of human pathogenic 
 
Neisseriae
 
 is the production and secretion of an immuno-
globulin (Ig)A1-specific serine protease (IgA1 protease) that cleaves preferentially human IgA1
and other target proteins. Here we show a novel function for native IgA1 protease, i.e., the
induction of proinflammatory cytokines such as tumor necrosis factor (TNF)-
 
a
 
, interleukin
(IL)-1
 
b
 
, IL-6, and IL-8 from peripheral blood mononuclear cells. The capacity of IgA1 pro-
tease to elicit such cytokine responses in monocytes was enhanced in the presence of T lym-
phocytes. IgA1 protease did not induce the regulatory cytokine IL-10, which was, however,
found in response to lipopolysaccharide and phytohemagglutinin. The immunomodulatory ef-
fects caused by IgA1 protease require a native form of the enzyme, and denaturation abolished
cytokine induction. However, the proteolytic activity is not required for the cytokine induc-
tion by IgA1 protease. Our results indicate that IgA1 protease exhibits important immunostim-
ulatory properties and may contribute substantially to the pathogenesis of neisserial infections
by inducing large amounts of TNF-
 
a
 
 and other proinflammatory cytokines. In particular, IgA1
protease may represent a key virulence determinant of bacterial meningitis.
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T
 
he 
 
Neisseriae
 
 are gram-negative, diplococcal bacteria
which primarily colonize human mucosal surfaces. Be-
sides several commensal species, the genus includes two hu-
 
man pathogens, 
 
Neisseria gonorrhoeae
 
 (gonococci), the causative
agent of gonorrhea, and 
 
Neisseria meningitidis
 
 (meningococci),
one major cause of bacterial meningitis. Both pathogens
exclusively colonize or infect humans as their natural hosts.
Gonococci induce a local inflammatory response of the
urogenital mucosa (1). Meningococci are mostly harmless
colonizers of the respiratory tract (e.g., nasopharynx). Un-
der some not yet fully understood circumstances, meningo-
cocci disseminate from locally infected tissues into the
blood stream and penetrate the blood–brain barrier to cause
severe inflammations in the central nervous system (2).
Various bacterial components have been implicated in
the pathogenesis of neisserial infections (3–6). Pili and Opa
proteins contribute to the attachment and the invasion of
different host cells, and the outer membrane porin protein I
or PorB was found to prevent the microbicidal activities of
phagocytes (7, 5) and to induce apoptosis in target cells (8).
Circumstantial evidence related to the unique association
of IgA1 proteases with human pathogenic bacterial species
(9, 6) suggests that this enzyme plays a significant role in
pathogenesis. IgA1 proteases are produced by a variety of
gram-positive and gram-negative human pathogens (10–12).
Among those, the IgA1 proteases of the pathogenic 
 
Neisse-
riae
 
 and various 
 
Haemophilus
 
 species are structurally closely
related (13, 14). They undergo frequent horizontal exchange
across the species barrier, thus forming a polymorphic class
of proteins (15, 16). The gram-negative bacterial IgA1 pro-
teases are derived from a polyprotein precursor molecule
which directs enzyme secretion by an autocatalytic process.
While the neisserial IgA1 protease precursors include two
additional secreted domains, an 
 
a
 
-protein and a 
 
g
 
-peptide
(13), the proteases of the two species probably exhibit sim-
ilar functions.
IgA1 protease cleaves human IgA1 both in serum and at
mucosal surfaces of the respiratory and urogenital tracts (10,
17). In particular, the neisserial IgA1 protease is a sequence-
specific endopeptidase which cleaves single peptide bonds
of distinct proline-rich consensus sequences that are found
in the hinge region of human IgA1 but not IgA2 (10, 18).
As a consequence, the enzymatic activity or characteristic
cleavage products of IgA1 molecules were found in na-
sopharyngeal and vaginal secretions of individuals infected
with pathogenic 
 
Neisseriae
 
 (11, 19, 20). As intact IgA1 pro-
tects against microorganisms infecting mucosal tissues by
prevention of microbial adherence, toxin neutralization, 
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and activation of Fc-
 
a
 
 receptor–dependent phagocytosis,
the cleavage of IgA1 has been postulated to impair IgA1-
mediated effector functions (11, 12). However, most indi-
viduals have neutralizing antibodies against IgA1 protease
that may interfere with the function of the enzyme (21–23).
Thus, the role of IgA1 protease in neisserial pathogenesis
remains obscure.
Inflammatory cytokines such as TNF-
 
a
 
, IL-1
 
b
 
, IL-6, and
IL-8 are produced by activated monocytes/macrophages.
They promote local inflammatory responses at the sites of
microbial infections, and mediate adherence of leukocytes
to the endothelial tissues and their transmigration by up-
regulating the expression of adhesion molecules (24–27).
Elevated levels of TNF-
 
a
 
, IL-1, IL-6, and IL-8 have
been  found in the cerebrospinal fluid (CSF)
 
1
 
 and plasma of
patients with meningitis (28–31) and were detected in
the urine after the intraurethral challenge of patients with
 
N. gonorrhoeae
 
 (32).
Besides LPS, several bacterial products that can stimulate
cytokine synthesis in different cell types have been charac-
terized (33). These cytokine-inducing agents include heat
labile proteins, glycoproteins, lipoproteins, or peptides, which
trigger cytokine synthesis by mechanisms distinct from LPS
and therefore form an additional class of virulence factors
termed modulins (34, 35).
The purpose of this study was to assess the immunogenic
and immunomodulatory properties of the neisserial IgA1
protease. We demonstrated that purified IgA1 protease acts
like a modulin by stimulating the release of TNF-
 
a
 
, IL-1
 
b
 
,
IL-6, and IL-8 from PBMCs. These effects were indepen-
dent of the proteolytic activity but required the native form
of the enzyme.
 
Materials and Methods
 
Purification and Characterization of Recombinant IgA1 Protease.
 
In this study, we used the recombinant form of IgA1 protease ex-
pressed in 
 
Escherichia coli
 
 strain H2053, which harbors plasmid
pIP11 containing the 
 
iga 
 
gene of 
 
N. gonorrhoeae
 
 MS11 with the
temperature-inducible bacteriophage 
 
l
 
 promoter P
 
L
 
, as described
previously (18). In brief, the supernatant of a 4-liter stationary phase
culture was recovered by centrifugation, supplemented with 0.1 M
EDTA, and diluted 1:1 (vol/vol) with potassium phosphate
buffer (20 mM, pH 7.0). The bacterial supernatant was applied
to a cation exchange column. After washing, bound protein was
eluted with 500 mM potassium phosphate, 8.6% glycerol. Frac-
tions of 10 ml were collected, precipitated with ammonium sul-
phate, and then redissolved in gel filtration buffer. Gel filtration
was performed with a preequilibrated Superdex column (Amer-
sham Pharmacia Biotech). Protein-containing eluates were rec-
ognized by UV absorption, pooled, and precipitated with ammo-
nium sulphate. Finally, the pellet was suspended in PBS and
dialyzed against PBS, pH 7.4, and stored in aliquots at 
 
2
 
70
 
8
 
C.
Purity of the protein was assessed by SDS-PAGE with subsequent
Coomassie staining showing the characteristic protein profile
with the typical 109- and 106-kD protein bands as described pre-
viously (18). The protein concentration was determined using a
 
commercial protein determination assay (Bio-Rad). Specificity for
IgA1 protease was confirmed by immunoblotting using an IgA1
protease–specific rabbit antiserum (13). The cleavage activity of
the recombinant IgA1 protease was determined with human IgA1
(20 ng/
 
m
 
l; Dakopatts) in Tris buffer (0.05 M Tris-HCl, 10 mM
CaCl
 
2
 
,
 
 
 
and 10 mM MgCl
 
2
 
, pH 7.5) at 37
 
8
 
C according to the
method described previously (36). Heat denaturation (boiling for
10 min) completely destroyed the enzymatic activity. The enzy-
matic activity could also be blocked by addition of the specific
peptide prolyl boronic acid inhibitor (37). 100 
 
m
 
M of the inhibi-
tor (provided by A.G. Plaut, New England Medical Center, Bos-
ton, MA) abrogated cleavage of IgA at concentrations up to 10
ng per 
 
m
 
l of IgA1 protease (data not shown).
 
Endotoxin Assays.
 
The endotoxin contents of our IgA1 pro-
tease preparations were determined by 
 
Limulus 
 
amebocyte lysate
assay (LAL; Haemochrom Diagnostica). All preparations con-
tained 
 
,
 
2 pg of endotoxin per 
 
m
 
g protein. It is described that
some proteins could interfere with the 
 
Limulus
 
 assay (38). To en-
sure that IgA1 protease is free of LPS, we have tested in addition
the priming potency of IgA1 protease for neutrophils, which are
as sensitive as the 
 
Limulus
 
 assay in detecting LPS. Different types
of LPS can prime neutrophils to increase their oxidative response
after stimulation with the agonist fMLP (Sigma Chemical Co.)
(38). PMNs preincubated with 10 
 
m
 
g/ml IgA1 protease for 30 min
stimulated with 1 
 
m
 
M fMLP showed no alteration of the oxida-
tive response compared with the control when measured as luminol-
dependent chemiluminescence in a six-channel Biolumat LB 9505
(Berthold; data not shown).
 
Cells.
 
PBMCs were isolated from buffy coats or freshly citrated
blood of adult, healthy volunteers
 
 
 
by density gradient centrifuga-
tion over Ficoll/Isopaque (Amersham Pharmacia Biotech) and
washed twice in Ca
 
2
 
, Mg
 
2
 
1
 
–free PBS. For some experiments,
lymphocytes and monocytes were separated (6 
 
3
 
 10
 
6
 
 cells/ml in
PBS plus 0.5% BSA) by counterflow centrifugation (elutriation)
using the Beckman J6ML/JE-5.0 centrifuge system. Elutriation
was performed at constant rotor speed with increasing flow rates,
and lymphocytes were collected. To obtain purified T cells, the
lymphocyte suspensions were positively sorted by anti-CD3
magnetic beads (MACS; Miltenyi Biotec). Purity of CD3
 
1
 
 T
cells was always 
 
.
 
95% as determined by flow cytometry. Mono-
cytes were prepared from PBMCs either by adherence to plastic
dishes (1 h, 37
 
8
 
C) or by negative selection using the MACS
monocyte isolation kit (Miltenyi Biotec). The purity of CD14
 
1
 
cells was always 
 
.
 
85% as measured by flow cytometry using a
PE-conjugated anti-CD14 antibody (Leu M3; Becton Dickinson).
The remaining 15% consisted of CD3
 
2
 
, CD19
 
2
 
, and CD56
 
2
 
flow cytometric counting events.
The monocytic cell line MonoMac 6 (no. 124; American
Type Culture Collection) was obtained from the German Col-
lection of Microorganism and Cell Cultures (Braunschweig, Ger-
many) and maintained in 24-well plates under low endotoxin
conditions (
 
,
 
10 pg/ml) in RPMI 1640 supplemented with 10%
heat-inactivated FCS, 2 mM 
 
l
 
-glutamine, 1% nonessential amino
acids, 1 mM sodium pyruvate, and 9 
 
m
 
g/ml bovine insulin as de-
scribed (39). The cell line normally expresses CD14 as controlled
by flow cytometry.
 
Cell Viability.
 
Cytotoxic effects of IgA1 protease preparations
were excluded by staining of PBMCs with propidium iodide (10
 
m
 
g/ml) and subsequent evaluation by flow cytometry. Cell via-
bility of freshly isolated or cultured cells (24 h with 10 
 
m
 
g/ml
IgA1 protease) was 
 
.
 
95% in all experiments.
 
Cell Culture and Stimulation of Cytokine Release.
 
All cell cul-
tures were performed in RPMI 1640 supplemented with 20 nM
 
1
 
Abbreviation used in this paper:
 
 CSF, cerebrospinal fluid. 
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l
 
-glutamine, 25 mM Hepes (GIBCO BRL), 500 U/ml penicil-
lin, 500 
 
m
 
g/ml streptomycin, and 5% heat-inactivated human AB
serum (pooled male serum, 
 
,,
 
1 ng/ml endotoxin; Sigma Chem-
ical Co.). This medium is further designated as culture medium.
A total of 10
 
5
 
 cells was cultured in 200 
 
m
 
l culture medium
in round-bottomed 96-well plates at 37
 
8
 
C, 5% CO
 
2
 
. MonoMac
6 cells (10
 
5
 
 cells/well) were incubated for 24 h in 96-well flat-bot-
tomed plates with culture medium. Cell-free supernatants were har-
vested after 18 h (150 
 
m
 
l/well, three wells per independent experi-
ment), pooled, and frozen in 50 
 
m
 
l aliquots at 
 
2
 
20
 
8
 
C until assayed.
To investigate the effect of CD3
 
1
 
 T lymphocytes on the IgA1
protease–induced cytokine production of CD14
 
1
 
 monocytes, 2 
 
3
 
10
 
4
 
 CD14
 
1
 
 cells were cultured either with or without CD3
 
1
 
cells keeping the monocyte/lymphocyte ratio constantly at 1:4. A
total of 10
 
5
 
 PBMCs were cultured as a control with a monocyte
content ranging from 10 to 20%.
 
Cytokine ELISAs.
 
The levels of the released cytokines TNF-
 
a
 
,
IL-1
 
b
 
, IL-6, IL-8 (R&D Systems), and IFN-
 
g
 
, GM-CSF, and
IL-10 (PharMingen) in the culture supernatants were quantified
with commercially available sandwich ELISA kits. The assays were
performed as recommended by the manufacturer. In brief, polysty-
rene microtiter plates were coated with the catching mAb over-
night, washed intensively (washing buffer: PBS, 0.02% Tween 20),
and blocked with PBS, 5% AB serum. Different dilutions of all sam-
ples and the standard cytokine dilutions were assayed in duplicate or
triplicate, respectively, with a total volume of 100 
 
m
 
l for 2 h at
room temperature. After removing the unbound detecting mAb by
washing (10 times), streptavidin-peroxidase solution was added to
each well and incubated for 20 min. After 10 washes, the chromo-
genic substrate (TMB substrate with H
 
2
 
O
 
2
 
; Kirkegaard & Perry)
was added to each well and color development was stopped after 20
min by adding 50 
 
m
 
l 1 M H
 
3
 
PO
 
4
 
. The absorbance of the samples
was measured at 450 nm. The cytokine concentrations were deter-
mined by extrapolating from the standard curve. The results are ex-
pressed as means of triplicates in ng/ml. The detection limits of the
ELISA kits were as follows: TNF-
 
a
 
, IL-1
 
b
 
, IL-10, GM-CSF, and
IFN-
 
g
 
 
 
# 
 
0.01 ng/ml; IL-6 and IL-8, 
 
# 
 
0.05 ng/ml.
 
Flow Cytometry.
 
For immunofluorescence staining, we used the
following: anti-CD14–PE as a monocytic marker (LeuM3, IgG2a;
Becton Dickinson), and FITC-conjugated anti–HLA-DR (B.812.2,
IgG2a; Coulter Immunotech) and anti-CD25 for detection of the
IL-2 receptor (ACT-1, IgG1; Dako). Control mouse Ig (IgG1-
FITC/IgG2a-PE) were obtained from Becton Dickinson. An
FITC-conjugated goat anti–mouse F(ab) fragment (Coulter Im-
munotech) was used as a secondary antibody. The cells were
washed, adjusted to 2 
 
3
 
 10
 
5
 
/200 
 
m
 
l in PBS with 0.2% BSA, and
incubated with the antibodies for 30 min on ice. After washing,
the samples were analyzed on a FACScalibur™ (Becton Dickin-
son) using the CELLQuest™ program. The cells were gated due
to their forward scatter/side scatter profile. Background levels of
immunofluorescence were determined using isotype control Ig.
For the detection of IL-2 receptor, cells were first labeled with
unconjugated anti-CD25, washed, and then incubated with
FITC-conjugated goat anti–mouse F(ab)
 
2
 
 fragment (5 
 
m
 
g/ml).
 
Proliferation Assay.
 
Proliferation assays with PBMCs (10
 
5
 
cells/well in culture medium) were performed at 37
 
8
 
C in 96-well
round-bottomed plates at a total of 150 
 
m
 
l/well. The cells were cul-
tured for various time periods (1–4 d) and pulsed with 18.5 kBq
of [
 
3
 
H]thymidine per well. Cells were then harvested on filters,
and incorporation of [3H]thymidine was measured using a Micro-
beta Scintillation Counter (Wallac Instruments). Unstimulated cells
and PHA-stimulated (5 mg/ml) cells were used as controls.
Figure 1. Purified IgA1 protease induces dose-dependent release of
TNF-a from PBMCs. On the top axis, LPS concentrations were set ac-
cording to the endotoxin content in the IgA1 protease protein on the bot-
tom axis. TNF-a synthesis induced by LPS and IgA1 protease is shown by
, and d, respectively. PBMCs were cultured for 18 h in the presence of
IgA1 protease or LPS. TNF-a was measured in pooled cell-free culture
supernatants by a specific ELISA. TNF-a levels in nonstimulated control
cells (medium control) did not exceed 0.02 ng/ml. Data were confirmed
by three experiments using PBMCs from different donors.
Table I. Dose-dependent Cytokine Induction by Purified IgA1 Protease and LPS from E. coli
Cytokine* Control‡
IgA1 protease (mg/ml) LPS (ng/ml)
0.1 1.0 3.0 10 0.03 30
IL-1b, 0.01 0.02 6 0.0 0.1 6 0.0 0.31 6 0.02 0.75 6 0.05 ,0.01 0.99 6 0.09
IL-6 0.2 6 0.0 0.3 6 0.1 19.5 6 0.5 14.3 6 2.3 24.5 6 1.7 ND 26.1 6 2.5
IL-8 7 6 0.5 15 6 1.9 29.8 6 3.6 33.1 6 1.8 64.24 6 6.1 21 6 1.1 45.3 6 2.6
*Cytokine levels in culture supernatants from PBMCs incubated for 18 h in the presence of different concentrations of IgA1 protease and E. coli
LPS. Values are the means 6 SD from triplicate wells. Amounts are given in ng/ml; IL-1b (detection limit 10 pg/ml), and IL-6 and IL-8 (detection
limit 50 pg/ml).
‡Culture medium was used as a control.1052 IgA1 Protease Stimulates Cytokine Production
Statistical Analyses. The nonparametric Wilcoxon rank test was
performed for comparison of cytokine data of PHA-, LPS-, and
IgA1 protease–stimulated PBMCs. Statistical differences were
considered significant at P , 0.01. Data from separate experiments
were expressed as means 6 SEM and were evaluated for statistical
significance by Student’s t test. Data from a single representative
experiment are presented as means 6 SD obtained by triplicate
determination.
Results
Induction of Proinflammatory Cytokine Release from Human
PBMCs by IgA1 Protease. To assess the production of the
proinflammatory cytokines TNF-a, IL-1b, IL-6, and IL-8,
PBMCs from healthy human donors were incubated with
purified IgA1 protease. LPS, PHA, and medium alone were
used as control. Initial experiments showed that release of
proinflammatory cytokines from PBMCs induced by IgA1
protease reached maximal levels between 12 and 24 h (data
not shown). Furthermore, a rapid decrease in IgA1 protease–
induced cytokine production could be observed after 24 h,
and only small amounts of TNF-a were detectable after 72 h.
Therefore, in subsequent experiments a single end-point of
18 h culture was chosen that allowed detection of TNF-a
and other proinflammatory cytokines. IgA1 protease stimu-
lated the release of proinflammatory cytokines by PBMCs in
a dose-dependent manner (Fig. 1, and Table I). Significant
amounts of TNF-a in the supernatants were already detect-
able in the presence of 1 mg/ml IgA1 protease, and highest
levels were reached using 10 mg/ml. Similar dose–response
patterns were obtained for other proinflammatory cytokines
such as IL-1b, IL-6, and the chemokine IL-8. Nonstimu-
lated PBMCs produced negligible amounts of TNF-a, IL-1b,
and IL-6, but some IL-8, which was probably induced by
adherence as previously postulated by Kasahara et al. (40).
To determine whether the cytokine induction was due
to LPS present in the preparation of the recombinant IgA1
protease from E. coli, we tested the potential of E. coli LPS
to induce TNF-a. The endotoxin content present in the
protease preparation of 10 mg/ml did not exceed 20 pg/ml.
As shown in Fig. 1, no significant cytokine production
compared with the control was detected at 10–30 pg/ml
LPS, indicating that endotoxin contamination was not the
cause of cytokine induction by purified IgA1 protease.
TNF-a synthesis in response to 10 mg/ml IgA1 protease
reached the level synthesized by cells stimulated with a
much higher dose of E. coli LPS (30 ng/ml). In subsequent
experiments, low dose (30 pg/ml) and high dose (30 ng/ml)
controls of LPS were always included.
The cytokine release of PBMCs showed similar varia-
tions between different donors upon stimulation with either
IgA1 protease, LPS, or PHA. As shown in Fig. 2 (A–D), the
median levels of the proinflammatory cytokines detected in
the presence of 10 mg/ml IgA1 protease were approximately
similar to those found after LPS stimulation and sometimes
even higher than those incubated with the lectin PHA.
Heat denaturation abolished the cytokine-inducing ca-
pacity of IgA1 protease (data not shown). To test whether the
Figure 2. Comparison of cytokine production by PBMCs from differ-
ent donors. PBMCs were cultured under low endotoxin conditions (,10
pg/ml as determined by the Limulus amebocyte lysate [LAL] assay). The
indicated stimuli were added to the medium at the following concentra-
tions: LPS, 30 ng/ml; PHA, 5 mg/ml; and IgA1 protease, 10 mg/ml. The
cell-free supernatants were harvested after 18 h, pooled, and analyzed for
the indicated cytokines by ELISA. Plots include data from n 5 15 (for
TNF-a [A] and IL-6 [C]) or n 5 12 (for IL-1b [B] and IL-8 [D]) inde-
pendent experiments. Boxes represent second and third quartiles; the lines
within each box are the median values; the error bars represent 5 and 95%
confidence. To compare cytokine levels in the different stimulation
groups, the nonparametric Wilcoxon rank test was used. Results are con-
sidered as significantly different from values obtained with medium alone
(*P , 0.05) and as significantly different from PHA (**P , 0.01).1053 Lorenzen et al.
enzymatic activity is involved in that process, PBMCs were
incubated in the presence of 100 mM of a specific IgA1
protease inhibitor (peptide prolyl boronic acid [37]). Al-
though at this concentration the inhibitor completely blocked
the cleavage of IgA1, it altered neither the LPS- nor the
IgA1 protease–induced production of proinflammatory cy-
tokines (data not shown). This demonstrates that the native
form but not the enzymatic activity of IgA1 protease is re-
quired for the induction of proinflammatory cytokines.
Cytokine Release Induced by IgA1 Protease Is Augmented in
the Presence of T Cells. IgA1 protease triggers a strong re-
lease of proinflammatory cytokines from PBMCs after only
a short incubation period, indicating that monocytes might
be the main producer of these mediators. To determine the
source of cytokine release, we cultivated lymphocyte-depleted
peripheral blood monocytes (purity varied between 85 and
95%). As demonstrated in Fig. 3, IgA1 protease induced
significantly lower amounts of TNF-a, IL-1b, IL-6, and
IL-8 compared with LPS, which readily stimulated TNF-a
production in purified monocytes. Direct comparison with
PBMCs revealed that IgA1 protease–stimulated PBMCs
can elicit up to 20-fold higher amounts of these cytokines
compared with the respective lymphocyte-depleted mono-
cyte cultures, which was particularly true for IL-6 and IL-8
(data not shown; see also Fig. 2). We also tested the mono-
cytic cell line, MonoMac 6. This cell line shows phenotypic
and functional characteristics of mature blood monocytes
and produces IL-1, IL-6, and TNF-a upon stimulation with
LPS or PMA (39, 41). Compared with LPS, we found a
significantly lower production of these cytokines and IL-8
after stimulation with IgA1 protease (Table II).
Direct contact with T cells can augment monocyte cyto-
kine production (42). To examine the necessity of cell
contact for TNF-a release in the different types of stimula-
tion, monocytes stimulated with IgA1 protease, LPS, or PHA
were incubated with autologous active and fixed (15 min,
paraformaldehyde at 08C) lymphocytes at a monocyte/
lymphocyte ratio of 1:2. In parallel, the lymphocytes and
monocytes were incubated alone. Such lymphocytes and
purified monocytes produced only low levels of TNF-a
upon stimulation with 10 mg/ml IgA1 protease (Fig. 4). The
same results were obtained after stimulation with PHA. The
addition of viable lymphocytes increased the TNF-a secre-
tion in nonstimulated, IgA1 protease–, and PHA-treated
monocytes, whereas the addition of prefixed lymphocytes
did not. Monocytes stimulated with IgA1 protease or PHA
also showed a significantly stronger TNF-a induction in the
presence of lymphocytes compared with the control. Only
LPS was able to induce TNF-a in purified monocytes alone,
and this was not further enhanced by lymphocytes.
To examine the particular role of T cells for IgA1 pro-
tease–induced TNF-a release, monocytes were incubated
Table II. Release of Proinflammatory Cytokines in the Monocytic 
Cell Line, MonoMac 6
Cytokine‡
Proinflammatory cytokines* induced by:
Control§
IgA1
protease
(10
mg/ml)
LPS
(30
ng/ml)
PHA
(5 mg/ml)
PMA
(100
ng/ml)
TNF-a, dl 0.03 0.12 ,dl 0.29
IL-1b, dl 0.02 0.06 ,dl ND
IL-6 ,dl 0.59 23.37 ,dl 4.73
IL-8 2.02 12.21 84.96 11.28 67.96
*Cytokine concentrations in culture supernatants are given in ng/ml.
,dl, below detection limit.
‡MonoMac 6 cells were incubated at 106 cells/ml for 24 h, and super-
natants were analyzed for cytokine production. Values are means from
duplicate assays.
§Corresponding culture medium was used as a control.
Figure 3. Production of proinflammatory cytokines by purified mono-
cytes in medium alone (white bars) and in response to 30 ng/ml LPS
(hatched bars) or 10 mg/ml IgA1 protease (black bars). The level of each
cytokine in the supernatant of stimulated monocyte cultures (105) was de-
termined after 18 h. The results shown here are mean values from three
different experiments 6 SEM.1054 IgA1 Protease Stimulates Cytokine Production
with autologous CD31 T lymphocytes at a monocyte/
lymphocyte ratio of 1:4. While T lymphocytes produced
no or very low amounts of TNF-a, the monocytes released
reduced levels of TNF-a in response to IgA1 protease
compared with crude PBMCs. Such reduced TNF-a secre-
tion of monocytes was enhanced in the presence of autolo-
gous purified T cells (Fig. 5). However, when the two cell
populations were separated by a permeable membrane dur-
ing the cell culture, the TNF-a release by monocytes was
not increased in response to IgA1 protease (data not
shown). These results suggest that direct contact between T
cells and monocytes is necessary for a maximum of cyto-
kine production by monocytes in response to IgA1 protease.
It is well known that lymphokines such as GM-CSF or
IFN-g can augment cytokine release in monocytes (43, 44).
We found increased levels of GM-CSF in PBMC cultures
after incubation with IgA1 protease for 18 h, whereas IgA1
protease failed to induce release of IFN-g after that time
(Fig. 6, A and B). Very low levels of IFN-g were finally de-
tectable after 4 d (data not shown). However, the IFN-g
levels in these cultures were always more than 100-fold
lower than peak levels of IFN-g in PHA-stimulated PBMC
cultures. Furthermore, in the first 4 d of culture, neither cell
proliferation nor increase of IL-2 receptor–positive lympho-
cytes could be measured after incubation with IgA1 protease
(data not shown). These results suggest that viable T cells are
required for the cytokine release by monocytes stimulated
with IgA1 protease, but unlike PHA, IgA1 protease does not
seem to provide a strong activation signal for T lymphocytes.
Effect of IgA1 Protease on IL-10 Production by PBMCs.
IL-10 is a cytokine with immunosuppressive and antiinflam-
matory effects on monocytes. Reportedly, IL-10 synthesis
is delayed relative to the synthesis of inflammatory cyto-
kines TNF-a, IL-1b, and IL-6 (45). In contrast to the in-
duction of proinflammatory cytokines, IgA1 protease failed
to induce IL-10, whereas LPS as well as PHA could stimu-
late IL-10 production in PBMCs (Fig. 7). Kinetic experiments
revealed that IgA1 protease does not induce IL-10 produc-
tion in PBMCs within a period up to 96 h. In contrast, cul-
ture supernatants of PHA- or LPS-stimulated PBMCs con-
tained high IL-10 levels at different time points (data not
shown).
Figure 4. PBLs enhance TNF-a release of monocytes. PBMCs were
separated by counterflow elutriation and adherence into monocytes (Mn)
and lymphocytes (Ly) as described in Materials and Methods. After 1 h
incubation, the autologous lymphocytes were added to the monocytes at
a monocyte/lymphocyte ratio of 1:2. Fixed lymphocytes were treated
with 2% paraformaldehyde (15 min at 08C). TNF-a levels in the superna-
tants were measured 18 h after stimulation with 30 ng/ml LPS, 5 mg/ml
PHA, or 10 mg/ml IgA1 protease.
Figure 5. Purified CD31 T lymphocytes enhance TNF-a production
of CD141 monocytes. The autologous CD31 T lymphocytes (T) were
added to the monocytes (Mn) at a monocyte/lymphocyte ratio of 1:4.
TNF-a levels in the supernatants were measured after 18 h of culture
with 10 mg/ml IgA1 protease. The results shown here are mean values
from three experiments from different donors 6 SEM (., s, and d).
Figure 6. GM-CSF (A) and IFN-g (B) release of PBMCs in response
to IgA1 protease (10 mg/ml), PHA (5 mg/ml), and LPS (30 ng/ml). The
levels of these cytokines were determined in supernatants after 18 h. The
results (means 6 SD of three determinations) were confirmed by three
independent experiments.1055 Lorenzen et al.
Discussion
IgA1 protease, a putative virulence factor of human
pathogenic  Neisseriae, was initially discovered as an enzyme
that cleaves human IgA1 molecules, thus interfering with
the biological functions of IgA1 (10). Here we report on a
novel property of neisserial IgA1 protease, the induction of
the proinflammatory cytokines TNF-a, IL-1b, and IL-6,
and the chemokine IL-8 in PBMCs.
The stimulation of cytokine synthesis by IgA1 protease
occurred in the nanomolar range and increased in a dose-
dependent manner. The level of cytokine release was sub-
stantial but varied to some extent depending on the donor.
The rapid cytokine induction within 24 h indicates a role of
monocytes/macrophages in this process. However, com-
pared with PBMCs, significantly lower amounts of TNF-a
and IL-8 and practically no IL-6 and IL-1b were elicited by
purified monocytes in response to IgA1 protease, whereas
LPS induced a strong cytokine secretion that included IL-6
and IL-1b. The monocytic cell line MonoMac 6 also
showed a low production of TNF-a, IL-1b, IL-6, and IL-8
in response to IgA1 protease. These results suggest that the
presence of lymphocytes is required for full cytokine induc-
tion by IgA1 protease.
It is known that the activation of monocytes/macrophages
and the release of monocyte-derived cytokines can be pro-
voked by either direct cell–cell contact with activated anti-
gen-specific T cells or secreted lymphokines (42–44, 46).
This is consistent with our finding that IgA1 protease–
induced TNF-a secretion by monocytes was enhanced by
the addition of lymphocytes or CD31 T cells to the cultures.
To investigate the role of activated T cells in this process, we
measured IFN-g secretion, CD69, and IL-2 receptor ex-
pression, representing typical markers of activated T cells.
Although CD69 was slightly upregulated, the low number
of IL-2 receptor–positive cells suggests that no large T cell
population was activated or that only partial activation oc-
curred (46; and data not shown). The T cell cytokine IFN-g
can enhance the cytokine expression in monocytes syner-
gistically in combination with GM-CSF (43, 44). Although
GM-CSF was detected after IgA1 stimulation, the release
of IFN-g was low and the addition of anti–IFN-g antibod-
ies had no effect on the monokine production (data not
shown). However, the fact that cocultivation with T cells
separated from the monocytes by a permeable membrane
could not enhance the production of proinflammatory cy-
tokines indicates that T cells may also participate by a yet
unknown contact-dependent mechanism or by nonclassical
presentation of antigen (47–49). We also did not find bind-
ing of IgA1 protease to T cells, whereas CD141 monocytes
were clearly stained with FITC-labeled IgA1 protease (data
not shown).
The profile of the cytokine response of PBMCs to IgA1
protease shows some similarities to LPS stimulation. Al-
though the IgA1 protease was produced as a recombinant
protein in E. coli, our preparations contained usually ,2 pg
LPS/mg protein. This LPS content could not sufficiently
induce the observed cytokine production. Furthermore, ef-
fects which are typically triggered by LPS, such as priming
of phagocytes for an enhancement of the oxidative burst,
could not be confirmed in cells incubated with IgA1 pro-
tease (38; and data not shown). On the other hand, LPS
does not require T cell engagement, suggesting that IgA1
protease functions by a different mechanism. Both mole-
cules can have synergistic effects in vitro (data not shown)
and may also act concertedly in vivo. Activated monocytes/
macrophages also produce the antiinflammatory cytokine
IL-10. This cytokine mediates important autoregulatory
effects by downregulating inflammation, and its maximal
production is delayed compared with the initial burst of
proinflammatory cytokines (45). IL-10 production was aug-
mented by stimulation with LPS or PHA, but not with IgA1
protease (50). Thus, IgA1 protease seems unique in stimu-
lating an asymmetric synthesis of proinflammatory cyto-
kines from monocytes and fails to induce strong regulatory
feedback loops.
Besides the neisserial IgA1 protease reported here, other
bacterial products have been found to induce proinflamma-
tory cytokines. These components have been classified as a
separate class of bacterial virulence factors termed modulins
(51, 34). Examples include the listeriolysin from Listeria mono-
cytogenes (52), the E. coli hemolysin (53), and the streptococ-
cal pneumolysin (54). Other proteins with enzymatic activ-
ity, such as the urease of Helicobacter pylori (55) and the
sphingomyelinase from Staphylococcus aureus (56), also modu-
late cytokine production. Only a few modulins, like the an-
thrax lethal toxin from Bacillus anthracis (34) and the clostrid-
ium toxin from Clostridium difficile (57), act in the attomolar
or femtomolar range, while most other modulins including
IgA1 protease exhibit their activity in the nanomolar range.
Some modulins, such the staphylococcal toxic shock syn-
drome toxin 1 (TSST-1) from S. aureus or the erythrogenic
exotoxin (ET) from Streptococcus pyogenes possess superanti-
genic activity, thereby inducing T cells to proliferate and to
produce cytokines (58). IgA1 protease is different from those
superantigenic factors because it is not a T cell mitogen.
Figure 7. IL-10 release by PBMCs stimulated with IgA1 protease (10
mg/ml), LPS (30 ng/ml), or PHA (5 mg/ml) after 18 h incubation. Cul-
ture medium alone was used as a control. The means 6 SEM of five in-
dependent experiments with PBMCs from five different donors are
shown.1056 IgA1 Protease Stimulates Cytokine Production
The property of neisserial IgA1 protease to induce
proinflammatory cytokines may be highly relevant for the
disease-causing properties of gonococci and meningococci.
A hallmark of the pathophysiology in these diseases is the
intense inflammatory response associated with the substantial
release of proinflammatory cytokines. TNF-a, IL-1, IL-6,
and IL-8 have been detected in local secretions and sera
during mucosal infections with gram-negative species, in-
cluding N. meningitidis and N. gonorrhoeae (29, 35). Increased
levels of IL-8 and TNF-a in particular in plasma and in
urine, and smaller amounts of IL-1b and IL-6 were found
in experimental gonorrhea after intraurethral application of
gonococci (32).
High levels of these cytokines were also found in the CSF
and in the serum during meningeal inflammation. These me-
diators promote the inflammatory response with subsequent
tissue damage and in some cases septic shock (28–30). The
level of TNF-a in the CSF directly correlates with the se-
verity of the damage to the blood–brain barrier (29).
The most important bacterial component of gram-nega-
tive bacteria known to stimulate the release of inflamma-
tory cytokines is LPS. Indeed, meningococcal LPS was
found to be a major cytokine-inducing component in bac-
terial meningitis, since the cytokine profile and levels found
in serum or CSF correlated with the LPS concentrations.
However, Prins et al. (59) could not confirm the relation-
ship between levels of cytokines and bacterial endotoxin
produced by various strains of young meningitis patients,
suggesting that factors other than endotoxin may be involved
in cytokine induction during acute meningococcal septic
shock. In vivo, LPS and IgA1 protease might be released
together and act synergistically. Strikingly, though, the three
major causative agents of bacterial meningitis, N. meningitidis,
H. influenzae, and Streptococcus pneumoniae, all produce an IgA1
protease (11, 13, 14, 60). Therefore, IgA1 protease may
constitute an underestimated virulence factor in sepsis and
meningeal infection.
Besides the cleavage of IgA1, several additional functions
have been attributed to neisserial IgA1 protease. IgA1 pro-
tease was recently shown to cleave LAMP-1, a lysosomal
protein associated with the endosomal maturation (36, 61),
but only one report suggested that, as a consequence, IgA1
protease facilitates the intracellular survival of pathogenic
N. gonorrhoeae (61). Furthermore, other human proteins
have been found to be proteolytic substrates in vitro. How-
ever, the biological relevance of their cleavage remains un-
clear. In a parallel study, we recently observed that IgA1
protease efficiently protects phagocytes from TNF-a–medi-
ated apoptosis (our unpublished results). Considering the
strong potential of IgA1 protease to induce TNF-a, this
observation is intriguing since Neisseria is capable of enter-
ing phagocytic cells by an active mechanism (62). Hence,
the pathogens may have an interest in preventing lethal ef-
fects of TNF-a on their intracellular niches.
The induction of proinflammatory cytokines may con-
tribute to the characteristic inflammatory reaction caused
by the pathogenic Neisseriae. Understanding the mechanism
of IgA1 protease in the regulation of these cytokines has
potential therapeutic significance and is currently in progress.
Future research should reveal strategies for blocking this
cytokine-inducing pathway in response to pathogenic Neis-
seriae and probably to other IgA1 protease–secreting human
pathogenic bacteria.
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